Gene Therapy Breakthroughs Offer New Hope for Children with Inherited Retinal Diseases
Recent advancements in gene therapy are bringing unprecedented hope to children and families affected by inherited retinal diseases (IRDs). Two significant developments highlight the transformative potential of these innovative treatments: a study demonstrating visual acuity improvements in AIPL1-associated IRDs and the successful restoration of sight in a young girl with RPE65-related Leber Congenital Amaurosis (LCA) through gene therapy. These breakthroughs underscore a pivotal moment in the fight against genetic blindness, offering the promise of improved vision and quality of life for young patients.
AIPL1 Gene Therapy Shows Significant Visual Improvement
A groundbreaking study has revealed substantial visual acuity improvements in children with AIPL1-associated inherited retinal dystrophies following gene therapy. Patients with this ultra-rare condition are typically born with severely impaired vision, often limited to light perception, due to mutations in the AIPL1 gene, which cause retinal cells to malfunction and die.
The gene therapy, delivered via a subretinal injection of a recombinant adeno-associated viral (AAV) vector containing a healthy copy of the AIPL1 gene, aims to restore essential protein function in retinal cells. In the initial cohort of four young children, aged one to three years, who received the therapy in one eye, significant improvements in visual acuity were observed three to four years post-treatment. Before the intervention, these children's vision was limited to light perception, equivalent to 2.7 logMAR. After treatment, their visual acuity improved to a mean of 0.9 logMAR, indicating a substantial gain in sight. Importantly, the untreated eyes showed no such improvement, and in fact, continued to lose sight, highlighting the therapy's protective benefit against degeneration.
Further expanding on these promising results, an additional seven children with AIPL1-associated severe retinal dystrophy have since been treated bilaterally, also showing substantial benefits. Researchers emphasize that early intervention, ideally before the age of four, is crucial for the effectiveness of this treatment, as retinal degeneration progresses rapidly after this age.
Life-Changing Treatment for RPE65-Related LCA
In another inspiring development, a six-year-old girl named Saffie Sandford, diagnosed with RPE65-related Leber Congenital Amaurosis (LCA), has had her sight restored thanks to life-changing gene therapy. Saffie's condition, caused by a mutation in the RPE65 gene, prevented her eye cells from producing a protein vital for normal vision, leading to poor sight from infancy and progressive vision loss.
Saffie received Luxturna (Voretigene Neparvovec), a gene therapy that delivers a healthy copy of the RPE65 gene directly into the eye. She underwent treatment in one eye in April 2025 and the second eye in September 2025, just before her sixth birthday. Her mother described the treatment as